CHRS vs OGN · rev $26.6M vs P/E 3.4, rev $3.02B
Coherus BioSciences Inc (CHRS) versus Organon & Co (OGN) — a side-by-side from cached financials, not a winner call.
Coherus BioSciences Inc (CHRS) is a biotechnology company listed on US.
Organon & Co (OGN) is a drug manufacturers - general company listed on US.
Latest reported CHRS revenue for 2026-06-30 was $26.6M. Net income was -$59.0M. CHRS currently screens at market cap $223.7M.
Latest reported OGN revenue for 2026-06-30 was $3.02B. Net income was $254.0M. OGN currently screens at market cap $2.52B and trailing P/E 3.4.
CHRS currently screens at market cap $223.7M. OGN currently screens at market cap $2.52B and trailing P/E 3.4.
Not investment advice. Open the CHRS and OGN stock pages for the full models.
Not investment advice.